Author:
Li Ying,Shen Lin,Yin Xudong,Chen Zixuan,Chen Yong
Subject
Infectious Diseases,Psychiatry and Mental health,Geriatrics and Gerontology,Public Health, Environmental and Occupational Health,Obstetrics and Gynecology,Health Policy,Pediatrics, Perinatology and Child Health,Internal Medicine
Reference12 articles.
1. Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis;Gao;Lancet Reg Health Western Pac,2023
2. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study;Sun;Lancet,2021
3. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma;Doki;N Engl J Med,2022
4. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial;Luo;JAMA,2021
5. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial;Lu;BMJ,2022